Of note, A549 is also a SMARCA4-deficient NSCLC cell line and this independent study does further support the notion of elevating IP3R3 expression to enhance chemotherapy response in SMARCA4/2-deficient cancers. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.